155 related articles for article (PubMed ID: 24375999)
1. Comparison of oral vancomycin capsule and solution for treatment of initial episode of severe Clostridium difficile Infection.
Bass SN; Lam SW; Bauer SR; Neuner EA
J Pharm Pract; 2015 Apr; 28(2):183-8. PubMed ID: 24375999
[TBL] [Abstract][Full Text] [Related]
2. Comparison of treatment outcomes with vancomycin alone versus combination therapy in severe Clostridium difficile infection.
Bass SN; Bauer SR; Neuner EA; Lam SW
J Hosp Infect; 2013 Sep; 85(1):22-7. PubMed ID: 23876778
[TBL] [Abstract][Full Text] [Related]
3. Effect of vancomycin dose on treatment outcomes in severe Clostridium difficile infection.
Lam SW; Bass SN; Neuner EA; Bauer SR
Int J Antimicrob Agents; 2013 Dec; 42(6):553-8. PubMed ID: 24103633
[TBL] [Abstract][Full Text] [Related]
4. Oral teicoplanin versus oral vancomycin for the treatment of severe Clostridium difficile infection: a prospective observational study.
Popovic N; Korac M; Nesic Z; Milosevic B; Urosevic A; Jevtovic D; Mitrovic N; Markovic A; Jordovic J; Katanic N; Barac A; Milosevic I
Eur J Clin Microbiol Infect Dis; 2018 Apr; 37(4):745-754. PubMed ID: 29299697
[TBL] [Abstract][Full Text] [Related]
5. Characterization of continued antibacterial therapy after diagnosis of hospital-onset Clostridium difficile infection: implications for antimicrobial stewardship.
Harpe SE; Inocencio TJ; Pakyz AL; Oinonen MJ; Polk RE
Pharmacotherapy; 2012 Aug; 32(8):744-54. PubMed ID: 23307522
[TBL] [Abstract][Full Text] [Related]
6. Oral Vancomycin Monotherapy Versus Combination Therapy in Solid Organ Transplant Recipients With Uncomplicated Clostridium difficile Infection: A Retrospective Cohort Study.
Korayem GB; Eljaaly K; Matthias KR; Zangeneh TT
Transplant Proc; 2018; 50(1):137-141. PubMed ID: 29407296
[TBL] [Abstract][Full Text] [Related]
7. Comparison of outcomes with vancomycin or metronidazole for mild-to-moderate Clostridium difficile associated diarrhea among solid organ transplant recipients: A retrospective cohort study.
Nguyen CT; Li J; Anders S; Garcia-Diaz J; Staffeld-Coit C; Hand J
Transpl Infect Dis; 2018 Jun; 20(3):e12867. PubMed ID: 29512244
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for systemic vancomycin exposure following administration of oral vancomycin for the treatment of Clostridium difficile infection.
Pettit NN; DePestel DD; Fohl AL; Eyler R; Carver PL
Pharmacotherapy; 2015 Feb; 35(2):119-26. PubMed ID: 25689243
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection.
Tieu JD; Williams RJ; Skrepnek GH; Gentry CA
J Clin Pharm Ther; 2019 Apr; 44(2):220-228. PubMed ID: 30350418
[TBL] [Abstract][Full Text] [Related]
10. Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based Clostridium difficile infection treatment policy.
Jardin CG; Palmer HR; Shah DN; Le F; Beyda ND; Jiang Z; Garey KW
J Hosp Infect; 2013 Sep; 85(1):28-32. PubMed ID: 23834988
[TBL] [Abstract][Full Text] [Related]
11. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
Cornely OA
Clin Microbiol Infect; 2012 Dec; 18 Suppl 6():28-35. PubMed ID: 23121552
[TBL] [Abstract][Full Text] [Related]
12. Retrospective evaluation of fidaxomicin versus oral vancomycin for treatment of Clostridium difficile infections in allogeneic stem cell transplant.
Prohaska L; Mahmoudjafari Z; Shune L; Singh A; Lin T; Abhyankar S; Ganguly S; Grauer D; McGuirk J; Clough L
Hematol Oncol Stem Cell Ther; 2018 Dec; 11(4):233-240. PubMed ID: 29928848
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Oral Vancomycin in Preventing Recurrent Clostridium difficile Infection in Patients Treated With Systemic Antimicrobial Agents.
Van Hise NW; Bryant AM; Hennessey EK; Crannage AJ; Khoury JA; Manian FA
Clin Infect Dis; 2016 Sep; 63(5):651-3. PubMed ID: 27318333
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a bedside scoring system for predicting clinical cure and recurrence of Clostridium difficile infections.
Jacobson SM; Slain D
Am J Health Syst Pharm; 2015 Nov; 72(21):1871-5. PubMed ID: 26490821
[TBL] [Abstract][Full Text] [Related]
15. Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population.
Morrisette T; Van Matre AG; Miller MA; Mueller SW; Bajrovic V; Abidi MZ; Benamu E; Kaiser JN; Barber GR; Chase S; Tobin J; Fish DN; Gutman JA
Biol Blood Marrow Transplant; 2019 Oct; 25(10):2091-2097. PubMed ID: 31255741
[TBL] [Abstract][Full Text] [Related]
16. Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study.
Gentry CA; Nguyen PK; Thind S; Kurdgelashvili G; Skrepnek GH; Williams RJ
Clin Microbiol Infect; 2019 Aug; 25(8):987-993. PubMed ID: 30583055
[TBL] [Abstract][Full Text] [Related]
17. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin.
Al-Nassir WN; Sethi AK; Nerandzic MM; Bobulsky GS; Jump RL; Donskey CJ
Clin Infect Dis; 2008 Jul; 47(1):56-62. PubMed ID: 18491964
[TBL] [Abstract][Full Text] [Related]
18. A real-world evaluation of oral vancomycin for severe Clostridium difficile infection: implications for antibiotic stewardship programs.
Le F; Arora V; Shah DN; Salazar M; Palmer HR; Garey KW
Pharmacotherapy; 2012 Feb; 32(2):129-34. PubMed ID: 22392421
[TBL] [Abstract][Full Text] [Related]
19. Impact of vancomycin faecal concentrations on clinical and microbiological outcomes in Clostridium difficile infection.
Thabit AK; Nicolau DP
Int J Antimicrob Agents; 2015 Aug; 46(2):205-8. PubMed ID: 26055927
[TBL] [Abstract][Full Text] [Related]
20. Clostridium difficile infection in the "oldest" old: clinical outcomes in patients aged 80 and older.
Cober ED; Malani PN
J Am Geriatr Soc; 2009 Apr; 57(4):659-62. PubMed ID: 19392957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
